Quest Adds BioMerieux's BRAF Mutation Test to its Melanoma CDx Offerings | GenomeWeb

NEW YORK (GenomeWeb) – Quest Diagnostics announced today it will offer BioMérieux's BRAF mutation companion diagnostic for two of GlaxoSmithKline's molecularly targeted melanoma drugs, Tafinlar (dabrafenib) and Mekinist (trametinib).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.